In: Journal of Antimicrobial Chemotherapy, 2016, vol. 71, no. 1, p. 156-161
|
In: Journal of Antimicrobial Chemotherapy, 2017, vol. 72, no. 11, p. 3070-3078
|
In: Journal of Antimicrobial Chemotherapy, 2020, p. dkaa487
Objectives: To evaluate the in vivo efficacy of a dual carbapenem combination containing imipenem plus meropenem against carbapenem-resistant Acinetobacter baumannii producing carbapenemases OXA-23 or OXA-58.Methods: An experimental model of peritonitis using C57BL/6J female mice was developed and the minimum lethal doses were calculated for infections due to OXA-23 or OXA-58 producers of A. ...
|
In: Journal of Antimicrobial Chemotherapy, 2020, vol. 75, no. 12, p. 3593–3600
Background: Carbapenemase-producing Enterobacterales represent a major therapeutic challenge. MBLs, requiring zinc at their catalytic site, could be inhibited by meso-dimercaptosuccinic acid (DMSA), a heavy metal chelator already widely used for treating lead intoxication.Objectives: To evaluate the activity of carbapenems alone or combined with DMSA against MBL-producing Escherichia coli in...
|
In: Intensive Care Medicine, 2014, vol. 40, no. 10, p. 1429-1448
|
In: Eurosurveillance, 2018, vol. 23, no. 8, p. 17–00078
An infection control programme was implemented in a 21,000-bed multihospital institution for controlling the spread of carbapenemase-producing Enterobacteriaceae (CPE) and glycopeptide-resistant Enterococcus faecium (GRE), classified as ‘emergent extensively drug-resistant bacteria’ (eXDR) in France. We evaluated factors associated with outbreaks occurrence (n = 103), which followed 901...
|
In: European Journal of Clinical Microbiology and Infectious Diseases, 2004, vol. 23, no. 3, p. 203-204
|
In: Intensive Care Medicine, 2005, vol. 31, no. 11, p. 1466-1468
|
In: Intensive Care Medicine, 2005, vol. 31, no. 11, p. 1514-1521
|
In: European Journal of Pediatrics, 2002, vol. 161, no. 8, p. 460-461
|